Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEC 100 and Docetaxel in Relapsed Non-Metastatic Breast Cancer
NCT00053911Phase 3Terminated
- Sponsor
- Unicancer
- Start
- Nov 2002
- Primary completion
- Apr 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, epirubicin, cyclophosphamide and docetaxel in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Disease-Free Survival at 5 years. Started Nov 2002; status: terminated.
02
Drugs
fluorouracilepirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00053911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053911.